Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE: BXCL501 for Acute Stress Reaction and PTSD Prevention After Motor Vehicle Collision
NCT06943404Phase 2Recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Feb 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dexmedetomidine in acute stress reaction (ASR), acute stress disorder (ASD), post-traumatic stress disorder (PTSD), sponsored by University of North Carolina at Chapel Hill. Started Feb 2026; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
acute stress reaction (ASR)acute stress disorder (ASD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06943404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943404.